Ira Zackon
YOU?
Author Swipe
View article: Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is)
Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitors (cBTKis) or B-cell lymphoma 2 inhibitors (BCL2is) Open
INTRODUCTION Advances in targeted therapies have resulted in extended survival for many pts with CLL/SLL. OS is a key endpoint in oncology, but in 1st Line CLL studies, it often takes longer to mature due to the disease's indolent nature; …
View article: Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting
Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting Open
Introduction Bruton tyrosine kinase inhibitors (BTKis) are considered safe and effective treatment for patients diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). To date, few studies have examined the r…
View article: Real-World Baseline Characteristics and Preliminary Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the US Community Oncology Practice Setting
Real-World Baseline Characteristics and Preliminary Outcomes in Patients with Myelofibrosis Treated with Momelotinib in the US Community Oncology Practice Setting Open
Background: Myelofibrosis (MF) is a rare and progressive hematologic malignancy characterized by key hallmarks, including anemia, thrombocytopenia, splenomegaly, and constitutional symptoms. Anemia, the need for red blood cell transfusions…
View article: Nonspecific Signs and/or Symptoms of Cancer: A Retrospective, Observational Analysis from a Secondary Care, US Community Oncology Dataset
Nonspecific Signs and/or Symptoms of Cancer: A Retrospective, Observational Analysis from a Secondary Care, US Community Oncology Dataset Open
To help determine the unmet need for improved diagnostic tools to evaluate patients with nonspecific signs and/or symptoms (NSSS) and suspicion of cancer, we examined patient characteristics, diagnostic journey, and cancer incidence of pat…
View article: Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting
Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting Open
BACKGROUND: The treatment landscape for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) has shifted with the introduction of second-generation Bruton tyrosine kinase (BTK) inhibitors. Few real-world studi…
View article: Hemorrhagic Cystitis Secondary to Adenovirus and BK Virus Infection in a Diffuse Large B-Cell Lymphoma Patient with Recent CAR T-Cell Therapy
Hemorrhagic Cystitis Secondary to Adenovirus and BK Virus Infection in a Diffuse Large B-Cell Lymphoma Patient with Recent CAR T-Cell Therapy Open
Patients who undergo chimeric antigen receptor T-cell therapy (CAR T-cell therapy) are immunosuppressed due to multiple factors. While adenovirus and BK virus are well-known pathogens in the context of hematopoietic stem cell transplant, t…
View article: A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma Open
Purpose: The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma. Evofosfamide (formerly TH-302) is a 2-nitroimidazole prodrug of the DNA alkylator, bromo-isophosphoramide mustard, which i…